The U.S. Food and Drug Administration on Wednesday warned about the risk of a rare but serious allergic reaction with the use ...
The U.S. Food and Drug Administration on Wednesday warned about the risk of a rare but serious allergic reaction with the use ...
People with multiple sclerosis (MS) face a significantly higher risk of perinatal mental illness compared to those with other ...
Hosted on MSN1d
Multiple Sclerosis May Worsen With Menopause TransitionThe menopausal transition may represent an inflection point for worsening of multiple sclerosis (MS) in women, according to a ...
MS patients who achieve long-term stable disease on disease-modifying therapy may want to stop their medication for varying ...
The FDA issued a boxed warning for anaphylaxis risk linked to Glatiramer acetate and Glatopa, used in MS treatment.
4d
The National Multiple Sclerosis Society, the leading global organization supporting and empowering people living with ...
GlobalData on MSN3d
FDA adds boxed warning to multiple sclerosis drugs after anaphylaxis casesTeva Pharmaceutical’s Copaxone was approved by the FDA in 1996 to treat relapsing forms of MS, an autoimmune disorder that ...
After years of legal wrangling surrounding Teva’s Copaxone, the latest hit to the lucrative multiple sclerosis drug comes in ...
A new study reveals that people with multiple sclerosis (MS) experience significantly higher rates of mental illness during ...
A recent study shows that menopause may worsen Multiple Sclerosis symptoms and accelerate its progression due to a decline in ...
The FDA has advised health care professionals and patients with multiple sclerosis that treatment with glatiramer acetate is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback